Moderna(MRNA.US)涨超6.7% CDC新规称接种新冠疫苗将基于个人决定

Core Insights - Moderna's stock price increased by over 6.7%, reaching $29.17, following the CDC's announcement regarding new vaccination guidelines [1] Group 1: CDC Vaccination Guidelines - The CDC has introduced a new immunization plan for adults and children, incorporating COVID-19 vaccines into an "individualized decision-making" model [1] - The new guidelines recommend that young children receive the varicella (chickenpox) vaccine separately, rather than in combination with measles, mumps, and rubella vaccines [1] - Jim O'Neill, the acting director of the CDC, stated that the new policy restores informed consent to medical practice, allowing for better discussions between doctors and patients regarding vaccine risks and benefits [1] Group 2: Target Population for COVID-19 Vaccination - The updated guidelines emphasize that the benefits of COVID-19 vaccination are greater for high-risk individuals under 65, while low-risk individuals can decide with their doctors whether to get vaccinated [1]